Lutathera

Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.

Pharma & Biotech

Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone

by Pallavi Madhiraju
October 12, 2026
0 Comments

Bristol Myers Squibb's RYZ101 meets its Phase 3 endpoint after lutetium-177 treatment, advancing alpha radiopharmaceutical development.

Read More

Representative image: A modern radioligand therapy manufacturing centre under construction in Texas, highlighting Novartis AG’s investment in U.S. oncology infrastructure and the growing race to scale precision cancer treatment supply chains.

Medical Devices & Diagnostics

Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology

by Pallavi Madhiraju
May 9, 2026
0 Comments

RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.

Read More